AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls
New York, Jan 8, 2026, 19:33 EST — After-hours AbbVie shares dropped 4% on Thursday, slipping to $224.13 in after-hours trading from a previous close of $233.41, as investors digested a profit forecast reduction linked to a hefty charge. The move matters because AbbVie is scrambling to make up lost ground after Humira’s patent expired, leaning heavily on acquisitions to…